Treatment of Respiratory Distress Syndrome (RDS)

Primary Treatment Approaches

Surfactant replacement therapy is the cornerstone of RDS treatment, significantly reducing mortality and respiratory morbidity in preterm infants with surfactant deficiency, as recommended by the American Academy of Pediatrics 1, 2
Animal-derived surfactants are more effective than first-generation synthetic surfactants, showing lower mortality rates (RR 0.86; 95% CI 0.76–0.98) and fewer pneumothoraces (RR 0.63; 95% CI 0.53–0.75) 3

Timing of Surfactant Administration

Early rescue surfactant (within 1-2 hours of birth) is superior to delayed treatment (≥2 hours), significantly decreasing mortality (RR 0.84; 95% CI 0.74-0.95), air leak (RR 0.61; 95% CI 0.48-0.78), and chronic lung disease (RR 0.69; 95% CI 0.55-0.86), according to the American Academy of Pediatrics 4, 5
The INSURE strategy (Intubation, Surfactant administration, and Extubation to CPAP) significantly reduces the need for mechanical ventilation (RR 0.67; 95% CI 0.57-0.79) and oxygen requirement at 28 days, as recommended by the American Academy of Pediatrics 4, 5

Respiratory Support Strategies

Continuous Positive Airway Pressure (CPAP) is recommended as initial respiratory support in preterm infants with RDS, with surfactant administered if respiratory distress worsens, according to the American Academy of Pediatrics 6
For infants requiring mechanical ventilation, expeditious changes in ventilator settings may be necessary after surfactant administration to minimize lung injury and air leak, as recommended by the American Academy of Pediatrics 7, 8

Surfactant Administration Techniques

Surfactant is traditionally administered through an endotracheal tube either as a bolus, in smaller aliquots, or by infusion, with the optimal method of administration remaining unclear, as stated by the American Academy of Pediatrics 7
The optimal method of administration remains unclear, as clinical trials show no significant differences in outcomes between bolus and infusion techniques, according to the American Academy of Pediatrics 7, 9

Treatment for Non-RDS Respiratory Disorders

Surfactant therapy may benefit late-preterm and term neonates with secondary surfactant deficiency from conditions such as meconium aspiration syndrome, pneumonia/sepsis, and pulmonary hemorrhage, as recommended by the American Academy of Pediatrics 1, 7, 8

Monitoring and Complications

Surfactant administration may cause transient airway obstruction, oxygen desaturation, bradycardia, and alterations in cerebral blood flow, and requires careful monitoring and adjustment of ventilator settings to prevent lung injury, as stated by the American Academy of Pediatrics 7, 8
Redosing should not be needed more frequently than every 12 hours unless surfactant is being inactivated by infection, meconium, or blood, according to the American Academy of Pediatrics 4, 7

Special Considerations

Antenatal steroids and postnatal surfactant work synergistically to reduce mortality and respiratory morbidity, as recommended by the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics 6
Surfactant therapy is not recommended for infants with congenital diaphragmatic hernia, as it has not shown improved outcomes, according to the American Academy of Pediatrics 8

Management of Respiratory Distress Syndrome in Neonates

Initial Management and Surfactant Administration

The American Academy of Pediatrics recommends early initiation of CPAP at or soon after birth as the first-line treatment for preterm infants with RDS, which helps maintain functional residual capacity and prevents alveolar collapse 10, 11, 12
Early CPAP with selective surfactant administration results in lower rates of bronchopulmonary dysplasia and death compared to prophylactic surfactant therapy, with a significant reduction in mortality (RR 0.53, 95% CI 0.34 to 0.83) 10, 13
Surfactant should be administered selectively to infants who show worsening respiratory distress despite CPAP support, and preterm infants born at <30 weeks' gestation who need mechanical ventilation because of severe RDS should receive surfactant after initial stabilization 11, 14, 15, 16

Special Considerations and Pitfalls

Antenatal steroids and postnatal surfactant work synergistically to reduce mortality, severity of RDS, and air leaks in preterm infants 13
Routine intubation with prophylactic surfactant is no longer recommended as the first-line approach for preterm infants with RDS, due to the increased risk of complications 10, 11

Surfactant Therapy for Preterm Infants with Respiratory Distress Syndrome

Initial Management

The American Academy of Pediatrics recommends starting with CPAP (5-6 cm H₂O) immediately after birth for spontaneously breathing preterm infants with respiratory distress, rather than routine intubation 17, 18, 19
Early CPAP with selective surfactant administration results in lower rates of bronchopulmonary dysplasia and death compared to prophylactic surfactant therapy (RR 0.53, 95% CI 0.34-0.83) 18

Surfactant Administration

The American Academy of Pediatrics guidelines provide stronger evidence (Level 1) supporting the CPAP-first approach with selective surfactant administration for preterm infants with severe RDS requiring mechanical ventilation 17, 18, 19
Early rescue surfactant (<2 hours of age) is superior to delayed treatment, significantly decreasing mortality (RR 0.84; 95% CI 0.74-0.95) 18

Special Considerations

The American Academy of Pediatrics recommends against using surfactant for congenital diaphragmatic hernia, as it has not shown improved outcomes 18
Antenatal steroids and postnatal surfactant work independently and additively, reducing mortality, severity of RDS, and air leaks more than either alone 18, 20, 21

Personnel and Administration

Surfactant administration requires specialized expertise and should be administered by or under supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants 17, 18, 19

Management of Neonatal Respiratory Distress Syndrome

Surfactant Therapy

The American Academy of Pediatrics recommends administering rescue surfactant therapy immediately after intubation and initiation of mechanical ventilation, as surfactant improves oxygenation and reduces the need for ECMO in neonates with pneumonia/sepsis and secondary surfactant deficiency 22, 23
Surfactant therapy in neonates with pneumonia/sepsis improves oxygenation and reduces ECMO requirements, though the evidence base is smaller than for primary RDS 22, 23
Pneumonia and infection can inactivate surfactant, potentially requiring more frequent redosing than the typical 12-hour interval 22

Repeat Surfactant Dosing Strategy

Plan for up to 3 additional doses in the first 48 hours if the infant continues to require mechanical ventilation with FiO2 ≥0.30, administering doses no more frequently than every 12 hours 22

Surfactant Therapy for Premature Infants with Respiratory Distress Syndrome

Introduction to Surfactant Therapy

The American Academy of Pediatrics recommends administering animal-derived surfactant (poractant alfa or beractant) as soon as possible after intubation for premature infants with Respiratory Distress Syndrome (RDS), with poractant alfa showing advantages in reducing mortality, need for repeat dosing, and faster extubation compared to beractant 24

Choice of Surfactant Preparation

Animal-derived surfactants (poractant alfa, beractant, calfactant) are superior to first-generation synthetic surfactants, demonstrating lower mortality rates (RR: 0.86; 95% CI: 0.76–0.98; NNT: 40) and fewer pneumothoraxes (RR: 0.63; 95% CI: 0.53–0.75; NNT: 22) 24, 25

Special Populations and Considerations

The American Academy of Pediatrics suggests that antenatal steroids and postnatal surfactant work independently and additively, reducing mortality, RDS severity, and air leaks more than either alone 24, 26, 25
Consider rescue surfactant for late-preterm and term neonates with secondary surfactant deficiency from meconium aspiration syndrome, pneumonia/sepsis, or pulmonary hemorrhage, as it improves oxygenation and reduces ECMO requirements 24

Personnel Requirements

Surfactant must be administered by or under supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants 24